Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-435-4 | CAS number: 3091-25-6
Immunotoxicity
Administrative data
- Endpoint:
- immunotoxicity: sub-chronic oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Data originally provided for the HPV programme, but study report it no longer available. Study summary provided for information purposes only.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
- Principles of method if other than guideline:
- Male and female rats were dosed in feed for 3 months with monooctyltin trichloride at 3, 10, 30, and 100 ppm.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Trichlorooctylstannane
- EC Number:
- 221-435-4
- EC Name:
- Trichlorooctylstannane
- Cas Number:
- 3091-25-6
- Molecular formula:
- C8H17Cl3Sn
- IUPAC Name:
- trichlorooctylstannane
- Details on test material:
- Monooctyltin Trichloride [CAS No. 3091-25-6]:Dioctyltin Dichloride [CAS No. 3542-36-7] (65:35% mixture)
Constituent 1
Test animals
- Species:
- rat
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- not specified
Doses / concentrations
- Remarks:
- Doses / Concentrations:
3, 10, 30, and 100 ppm
Basis:
no data
Results and discussion
Results of examinations
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- ignificant reduction in thymus weight observed in males and females in the 100 ppm dose group. Marginal decrease observed at 30 ppm. No histopathological changes were observed in the thymic tissue.
- Details on results:
- GROSS PATHOLOGY
Significant reduction in thymus weight observed in males and females in the 100 ppm dose group. Marginal decrease observed at 30 ppm. No histopathological changes were observed in the thymic tissue.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 0.87 mg/kg bw/day
- Based on:
- not specified
- Sex:
- male
- Dose descriptor:
- NOEL
- Effect level:
- 0.88 mg/kg bw/day
- Based on:
- not specified
- Sex:
- female
Applicant's summary and conclusion
- Conclusions:
- A significant reduction in thymus weight was observed in males and females in the 100 ppm dose group with less apparent decrease in the 30 ppm group. No histopathological changes were observed in the thymic tissue.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
